After several years of development, various countries will offer infants, pregnant women, and seniors therapeutic options to prevent respiratory syncytial virus (RSV) infections in 2023.
Driven by recent governmental authorizations, sales of RSV drugs are estimated to surpass $9 billion by 2029, a sizeable increase from the $1 billion forcasted by GlobalData plc in 2023.
Read More
